The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 31, 2016

Filed:

Feb. 08, 2013
Applicant:

The Regents of the University of Michigan, Ann Arbor, MI (US);

Inventors:

Suling Liu, Heifei, CN;

Max S. Wicha, Ann Arbor, MI (US);

Assignee:

Other;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/7088 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/7088 (2013.01); A61K 39/0011 (2013.01); A61K 45/06 (2013.01); C12N 15/1135 (2013.01); C12N 15/1136 (2013.01); C12N 15/1138 (2013.01); G01N 33/57484 (2013.01); A61K 2039/507 (2013.01); A61K 2039/5154 (2013.01); C12N 2310/113 (2013.01); C12N 2310/141 (2013.01); C12N 2320/31 (2013.01); C12N 2330/50 (2013.01);
Abstract

Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24−, EpCam−CD49P+ (for EMT cancers stem cells), ALDH+ and EPCam+CD49r− (for MET cancers stem cells), and CD44+CD24−ALDH+ (for EMT-MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).


Find Patent Forward Citations

Loading…